@article{236dffbf18ba46a2b8876ba5cb006e53,
title = "Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study",
abstract = "Type 1 diabetes mellitus (T1DM) is associated with a high risk of cardiovascular (CV) complications, even after controlling for traditional CV risk factors. Therefore, determinants of the residual increased CV morbidity and mortality remain to be discovered. This prospective cohort of people living with T1DM in France (SFDT1) will include adults and children aged over six years living with T1DM, recruited throughout metropolitan France and overseas French departments and territories. The primary objective is to better understand the parameters associated with CV complications in T1DM. Clinical data and biobank samples will be collected during routine visits every three years. Data from connected tools, including continuous glucose monitoring, will be available during the 10-year active follow-up. Patient-reported outcomes, psychological and socioeconomic information will also be collected either at visits or through web questionnaires accessible via the internet. Additionally, access to the national health data system (Health Data Hub) will provide information on healthcare and a passive 20-year medico-administrative follow-up. Using Health Data Hub, SFDT1 participants will be compared to non-diabetic individuals matched on age, gender, and residency area. The cohort is sponsored by the French-speaking Foundation for Diabetes Research (FFRD) and aims to include 15,000 participants.",
keywords = "Cardiovascular risk factors, Cohort, Glucose variability, Hypoglycaemia, Macroangiopathy, Quality of life, Type 1 diabetes",
author = "Riveline, {J. P.} and B. Verg{\'e}s and B. Detournay and S. Picard and Benhamou, {P. Y.} and E. Bismuth and L. Bordier and N. Jeandidier and M. Joubert and R. Roussel and A. Sola-Gazagnes and A. Bonnefond and S. Clavel and Velayoudom, {F. L.} and J. Beltrand and H. Hanaire and P. Fontaine and C. Thivolet and H. Servy and S. Tubiana and S. Lion and Gautier, {Jean Fran{\c c}ois} and Etienne Larger and E. Vicaut and L. Sablone and G. Fagherazzi and E. Cosson",
note = "Funding Information: JPR is an advisory panel member for Sanofi, MSD, Eli Lilly, Novo Nordisk, Abbott, Alphadiab, Air Liquide and Medtronic and has received research funding from and provided research support to Abbott, Air Liquide, Sanofi, and Novo Nordisk. BV is an advisory panel member for Astra Zeneca, Lilly, NovoNordisk and received speaker honoraria from Amgen, Astra Zeneca, Boehringer-Ingelheim, Lilly, NovoNordisk and Sanofi. BD is employed by CEMKA, a health economic and outcomes research team providing health studies and advisory services for private and public organisms. BD served as an advisor, consultant, or member of a speaker bureau for Merck Sharpe & Dohme Corp., Novo Nordisk, Pfizer Inc., Eli Lilly, Sanofi-Aventis, and Boehringer-Ingelheim. SP has received writing and consulting fees from Abbott, Air Liquide, Astra Zeneca, Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi, and VitalAire. PYB has received speaker honoraria from Abbott, Roche, Eli Lilly, Novo Nordisk and Sanofi, and served on advisory board panels for Abbott, Diabeloop, Roche, Medtronic, Dexcom, Insulet, LifeScaen, Eli Lilly, Novo Nordisk and Sanofi. HS is the main share owner and full-time employee of e-health Services Sano{\"i}a, a full service CRO providing digital and scientific services for real-world evidence studies promoted by private and public organisations. HH has received congress invitations, honoraria and consultancy fees from Abbott, Animas/Johnson & Johnson, Medtronic, Roche, Eli Lilly, Novo Nordisk and MSD, and served on advisory board panels for Diabeloop and Insulet. NJ has received speaker honoraria from Eli Lilly and Sanofi, served without fees on advisory boards for Defymed, Diabeloop and public services. J.-F.G. reports personal fees and nonfinancial support from Eli Lilly, personal fees and nonfinancial support from Novo Nordisk, personal fees and nonfinancial support from Gilead, and personal fees and nonfinancial support from AstraZeneca. GF is or has been a consultant, expert or invited speaker for the following companies: MSD, Lilly, Roche Diabetes Care, AstraZeneca, Danone Research, Diabeloop, Bristol Myers Squibb and L'Or{\'e}al R&D. MJ has received consulting/speaker fees and/or research grants from Abbott, Medtronic, Glooko, Lilly, Novonordisk, Sanofi, Dexcom, Astrazeneca, Amgen, MSD, BMS, Boehringer-Ingelheim, Pfizer, Roche Diabetes Care, Air Liquide Sant{\'e} International, Nestle Home Care, and Vitalaire. LB has received congress invitations, honoraria and consultancy fees from Abbott, Astra Zeneca, Roche, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Janssen, Novartis, Sanofi, Bayer, BD and MSD. EB has received consulting / speaker fees from Abbott, Lilly, Medtronic, Novo Nordisk, Insulet, and Orkyn. R.R. is an advisory panel member for AstraZeneca, Sanofi, Merck Sharp & Dohme (MSD), Eli Lilly, Boehringer Ingelheim, Mundipharma, and Novo Nordisk, and has received research funding from and provided research support to Diabnext, Sanofi, and Novo Nordisk. All honoraria were donated to the Foundation APHP for medical research. SL has no duality of interest to declare. FLV has received congress invitations and speaker fees from Sanofi and Novartis but unrelated to this specific work. PF has received consulting and speaker frees from MSD, Bayer, Sanofi, Novo Nordisk unrelated to this present work. ST has no commercial or other associations that might pose a conflict of interest. LS has no commercial or other associations that might pose a conflict of interest. EV has received consulting fees from Abbott unrelated to this present work. EC has received congress invitations, honoraria and consultancy fees from Abbott, AlphaDiab, Ascencia, Lilly, LVL medical, Medtronic, MSD, Novartis, Novo-Nordisk, Roche Diagnostics, Sanofi, and Ypsomed. Publisher Copyright: {\textcopyright} 2021 Elsevier Masson SAS",
year = "2022",
month = may,
doi = "10.1016/j.diabet.2021.101306",
language = "English",
volume = "48",
pages = "101306",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson s.r.l.",
number = "3",
}